Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
- PMID: 35216055
- PMCID: PMC8875233
- DOI: 10.3390/ijms23041935
Fragile X Syndrome: From Molecular Aspect to Clinical Treatment
Abstract
Fragile X syndrome (FXS) is a neurodevelopmental disorder caused by the full mutation as well as highly localized methylation of the fragile X mental retardation 1 (FMR1) gene on the long arm of the X chromosome. Children with FXS are commonly co-diagnosed with Autism Spectrum Disorder, attention and learning problems, anxiety, aggressive behavior and sleep disorder, and early interventions have improved many behavior symptoms associated with FXS. In this review, we performed a literature search of original and review articles data of clinical trials and book chapters using MEDLINE (1990-2021) and ClinicalTrials.gov. While we have reviewed the biological importance of the fragile X mental retardation protein (FMRP), the FXS phenotype, and current diagnosis techniques, the emphasis of this review is on clinical interventions. Early non-pharmacological interventions in combination with pharmacotherapy and targeted treatments aiming to reverse dysregulated brain pathways are the mainstream of treatment in FXS. Overall, early diagnosis and interventions are fundamental to achieve optimal clinical outcomes in FXS.
Keywords: FMR1 gene; FMRP; autism spectrum disorder; behavior problems; fragile X syndrome.
Conflict of interest statement
Randi J. Hagerman has received funding from the Azrieli Foundation and from Zynerba Pharmaceuticals to carry out treatment studies in FXS. She has also consulted with Zynerba Pharmaceuticals for the development of the fragile X protocol for such studies. Dejan B. Budimirovic has received funding from Seaside, Roche, Neuren, Pfizer, Shire, Lundbeck, Forest, Sunovion, SyneuRX, Alcobra, Akili, Medgenics, Purdue, Supernus as a main sub-investigator, and from Ovid and Zynerba Pharmaceuticals as a principal investigator on clinical trials. He also consulted on clinical trial outcome measures (Seaside, Ovid). All the above funding has been directed to Kennedy Krieger Institute/the Johns Hopkins Medical Institutions; Dejan B. Budimirovic receives no personal funds and the Institute has no relevant financial interest in any of the commercial entities listed. The other co-authors declare that they have no competing interests.
Figures
Similar articles
-
State-of-the-art therapies for fragile X syndrome.Dev Med Child Neurol. 2024 Jul;66(7):863-871. doi: 10.1111/dmcn.15885. Epub 2024 Feb 22. Dev Med Child Neurol. 2024. PMID: 38385885 Review.
-
Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.Adv Exp Med Biol. 2012;970:517-51. doi: 10.1007/978-3-7091-0932-8_23. Adv Exp Med Biol. 2012. PMID: 22351071 Review.
-
Unstable mutations in the FMR1 gene and the phenotypes.Adv Exp Med Biol. 2012;769:78-114. doi: 10.1007/978-1-4614-5434-2_6. Adv Exp Med Biol. 2012. PMID: 23560306 Free PMC article. Review.
-
Epigenetic characterization of the FMR1 gene and aberrant neurodevelopment in human induced pluripotent stem cell models of fragile X syndrome.PLoS One. 2011;6(10):e26203. doi: 10.1371/journal.pone.0026203. Epub 2011 Oct 12. PLoS One. 2011. PMID: 22022567 Free PMC article.
-
microRNAs and Fragile X Syndrome.Adv Exp Med Biol. 2015;888:107-21. doi: 10.1007/978-3-319-22671-2_7. Adv Exp Med Biol. 2015. PMID: 26663181
Cited by
-
State-of-the-art therapies for fragile X syndrome.Dev Med Child Neurol. 2024 Jul;66(7):863-871. doi: 10.1111/dmcn.15885. Epub 2024 Feb 22. Dev Med Child Neurol. 2024. PMID: 38385885 Review.
-
A novel combination treatment for fragile X syndrome predicted using computational methods.Brain Commun. 2024 Jan 15;6(1):fcad353. doi: 10.1093/braincomms/fcad353. eCollection 2024. Brain Commun. 2024. PMID: 38226317 Free PMC article.
-
Combined extended reality and reinforcement learning to promote healthcare and reduce social anxiety in fragile X syndrome: a new assessment tool and a rehabilitative strategy.Front Psychol. 2023 Dec 20;14:1273117. doi: 10.3389/fpsyg.2023.1273117. eCollection 2023. Front Psychol. 2023. PMID: 38179497 Free PMC article. No abstract available.
-
Transcranial direct current stimulation combined with speech therapy in Fragile X syndrome patients: a pilot study.Front Neurol. 2023 Dec 5;14:1268165. doi: 10.3389/fneur.2023.1268165. eCollection 2023. Front Neurol. 2023. PMID: 38116107 Free PMC article.
-
Neurodevelopment and early pharmacological interventions in Fragile X Syndrome.Front Neurosci. 2023 Aug 2;17:1213410. doi: 10.3389/fnins.2023.1213410. eCollection 2023. Front Neurosci. 2023. PMID: 37599992 Free PMC article. Review.
References
-
- Verkerk A.J., Pieretti M., Sutcliffe J.S., Fu Y.-H., Kuhl D.P., Pizzuti A., Reiner O., Richards S., Victoria M.F., Zhang F., et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell. 1991;65:905–914. doi: 10.1016/0092-8674(91)90397-H. - DOI - PubMed
-
- Weiler I.J., Irwin S.A., Klintsova A., Spencer C.M., Brazelton A.D., Miyashiro K., Comery T.A., Patel B., Eberwine J., Greenough W.T. Fragile X mental retardation protein is translated near synapses in response to neurotransmitter activation. Proc. Natl. Acad. Sci. USA. 1997;94:5395–5400. doi: 10.1073/pnas.94.10.5395. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical